PROFUSA INC (PFSA)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-14
$2.59+6.58%
Close 2026-09-14 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-14
Research Workspace
Put PFSA beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Manage financial obligations and capital allocation: New debt issued vs avoid dilution.
View ThesisManagement screens strong on capital allocation.
View ManagementThis stock is volatile — it swings about 6% on a typical day and fell roughly 100% in its worst 12-month stretch.
View RiskPFSA's growth depends on managing financial obligations and capital allocation effectively. Recent financial performance is strong, holding in the top half of its industry. Revenue growth is supported by favorable sector trends, with the price roughly in line with forecasted growth. PFSA trades at 1.6× price-to-sales, below the peer median of 2.9×. The primary risk is the pressure on managing financial obligations, as new debt was issued. Peer multiples imply a price about 65% above where it trades. This read is provisional; the thesis is on watch.
Trailing returns as of 2026-09-14. PFSA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Continue this research
Compare PFSA with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| PFSA Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 2 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put PFSA next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Manage financial obligations and capital allocation
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Equity purchase supports financial obligations and capital allocation.